Cargando…

Association between integrase strand transfer inhibitor (INSTIs) use with insulin resistance and incident diabetes mellitus in persons living with HIV: A systematic review and meta-analysis protocol

INTRODUCTION: Poeple living with HIV have higher prevalence of diabetes mellitus and metabolic perturbations compared to non-HIV populations. Diabetes and metabolic syndrome co-morbidities add significant burden to HIV care. Currently, WHO recommends integrase strand transfer inhibitors (INSTIs) as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mulindwa, Frank, Kamal, Habiba, Castelnuovo, Barbara, Bollinger, Robert C., Schwarz, Jean-Marc, Brussealers, Nele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890726/ https://www.ncbi.nlm.nih.gov/pubmed/35235607 http://dx.doi.org/10.1371/journal.pone.0264792

Ejemplares similares

Association between integrase strand transfer inhibitor use with insulin resistance and incident diabetes mellitus in persons living with HIV: a systematic review and meta-analysis
por: Mulindwa, Frank, et al.
Publicado: (2023)

Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan
por: Chang, Sui-Yuan, et al.
Publicado: (2016)

Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV
por: Dow, Dorothy E., et al.
Publicado: (2014)

1566. Determinants associated with weight gain among persons with HIV who switch to integrase strand transfer inhibitors (INSTI)
por: Cutshaw, Melissa Klein, et al.
Publicado: (2023)

A computational overview of integrase strand transfer inhibitors (INSTIs) against emerging and evolving drug-resistant HIV-1 integrase mutants
por: Sayyed, Sharif Karim, et al.
Publicado: (2023)

Prevalence of resistance to integrase strand-transfer inhibitors (INSTIs) among untreated HIV-1 infected patients in Morocco
por: Alaoui, Najwa, et al.
Publicado: (2018)

A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection
por: Zhao, Alexa Vyain, et al.
Publicado: (2022)

1043. The impact of integrase strand transfer inhibitors (InSTIs) on weight gain among adults with HIV in clinical care
por: Thatipelli, Sneha, et al.
Publicado: (2020)

META-INSTI: metabolic adverse events following integrase strand transfer inhibitor administration in spontaneous adverse event reports
por: Murray, Milena M, et al.
Publicado: (2023)

Durability of Integrase STrand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPO cohort
por: Focà, Emanuele, et al.
Publicado: (2021)

106. META-INSTI: Metabolic Adverse Events Following Integrase Strand Transfer Inhibitor Administration in Spontaneous Adverse Event Reports
por: Murray, Milena M, et al.
Publicado: (2020)

2492. Differences between Individuals Currently Taking Integrase Inhibitor (INSTI)-based Therapy and Those Not Taking INSTIs in the Era of INSTIs as Recommended First-line Therapy
por: Monroe, Anne K, et al.
Publicado: (2019)

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? A case report
por: Mulindwa, Frank, et al.
Publicado: (2023)

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
por: Mulindwa, Frank, et al.
Publicado: (2023)

Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort
por: Abdullahi, Adam, et al.
Publicado: (2023)

Integrase Strand Transfer Inhibitors in HIV Therapy
por: Mesplède, Thibault, et al.
Publicado: (2013)

Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravir
por: Mulindwa, Frank, et al.
Publicado: (2023)

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
por: Mulindwa, Frank, et al.
Publicado: (2023)

Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting
por: Greenberg, Lauren, et al.
Publicado: (2022)

Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted Susceptibility to INSTIs
por: Kirichenko, Alina, et al.
Publicado: (2020)

Pharmacokinetic drug interactions of integrase strand transfer inhibitors
por: Lu, Chi-Hua, et al.
Publicado: (2021)

HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment
por: Foster, Emma G., et al.
Publicado: (2022)

HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases
por: Zhao, Xue Zhi, et al.
Publicado: (2016)

Primary resistance against integrase strand transfer inhibitors in integrase strand transfer inhibitor-naive patients failing first- and second-line ART in Tanzania
por: Henerico, Shimba, et al.
Publicado: (2022)

Incidence of cardiometabolic outcomes among people living with HIV‐1 initiated on integrase strand transfer inhibitor versus non‐integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States
por: Rebeiro, Peter F., et al.
Publicado: (2023)

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
por: Mulindwa, Frank, et al.
Publicado: (2023)

3′-Processing and strand transfer catalysed by retroviral integrase in crystallo
por: Hare, Stephen, et al.
Publicado: (2012)

Multiple choices for HIV therapy with integrase strand transfer inhibitors
por: Raffi, Francois, et al.
Publicado: (2012)

Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors
por: Zhao, Xue Zhi, et al.
Publicado: (2017)

HIV drug resistance against strand transfer integrase inhibitors
por: Anstett, Kaitlin, et al.
Publicado: (2017)

Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs
por: Smith, Steven J., et al.
Publicado: (2021)

Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance
por: Richetta, Clémence, et al.
Publicado: (2022)

Pretreatment integrase strand transfer inhibitor resistance in Tianjin, China
por: Xia, Huan, et al.
Publicado: (2023)

1049. Weight Gain in Persons Living with HIV (PLWH) Treated with Bictegravir Compared to Other Integrase Strand Transfer Inhibitors
por: Fang, Michelle, et al.
Publicado: (2020)

Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks
por: Mulindwa, Frank, et al.
Publicado: (2023)

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors
por: Malet, Isabelle, et al.
Publicado: (2017)

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence
por: Mesplède, Thibault, et al.
Publicado: (2015)

HIV-1 integrase strand-transfer inhibitor resistance in southern Taiwan
por: Tsai, Hung-Chin, et al.
Publicado: (2018)

Inhibition of matrix metalloproteinases by HIV-1 integrase strand transfer inhibitors
por: Foster, Emma G., et al.
Publicado: (2023)

1563. Incidence of Errors in an INSTI-Based Era: A Comparison of Error Rates Between Single Versus Multiple Tablet INSTI-Based Regimens in the Inpatient Setting
por: Blackmon, Kayla, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2fvlgfqrb6ij7pl041uror8do2